Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection

Journal of Immunology

Volumn 180, Issue 2, 2008, Pages 948-956

  Du, Lanying ^a,c   Zhao, Guangyu ^b   Lin, Yongping ^a   Sui, Hongyan ^a   Chan, Chris ^a   Ma, Selene ^a   He, Yuxian ^c   Jiang, Shibo ^c   Wu, Changyou ^d   Yuen, Kwok Yung ^a   Jin, Dong Yan ^a   Zhou, Yusen ^b   Zheng, Bo Jian ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; RECOMBINANT ADENO ASSOCIATED VIRUS ENCODING RECEPTOR BINDING DOMAIN VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; IMMUNOGLOBULIN A; MEMBRANE PROTEIN; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; LUNG; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPLEEN; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; ADENO ASSOCIATED VIRUS; ANIMAL; ANTIBODY PRODUCTION; CELL STRAIN 3T3; DRUG EFFECT; GENETICS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; PHYSIOLOGY; VACCINATION; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; BALB 3T3 CELLS; DEPENDOVIRUS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; LUNG; MEMBRANE GLYCOPROTEINS; MICE; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 40449085104     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.2.948     Document Type: Article

References (66)

1. Peiris, J. S., S. T. Lai, L. L. Poon, Y. Guan, L. Y. Yam, W. Lim, J. Nicholls, W. K. Yee, W. W. Yan, M. T. Cheung, et al. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319-1325.
2. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J. A. Comer, W. Lim, et al. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1953-1966.
3. Zhong, N. S., B. J. Zheng, Y. M. Li, Poon, Z. H. Xie, K. H. Chan, P. H. Li, S. Y. Tan, Q. Chang, J. P. Xie, et al. 2003. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 362: 1353-1358.
4. Guan, Y., B. J. Zheng, Y. Q. He, X. L. Liu, Z. X. Zhuang, C. L. Cheung, S. W. Luo, P. H. Li, L. J. Zhang, Y. J. Guan, et al. 2003. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
5. Lau, S. K., P. C. Woo, K. S. Li, Y. Huang, H. W. Tsoi, B. H. Wong, S. S. Wong, S. Y. Leung, K. H. Chan, and K. Y. Yuen. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA 102: 14040-14045.
6. Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, H. Wang, G. Crameri, Z. Hu, H. Zhang, et al. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310: 676-679.
7. Chan, C. P., K. L. Siu, K. T. Chin, K. Y. Yuen, B. Zheng, and D. Y. Jin. 2006. Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J. Virol. 80: 9279-9287.
8. Holmes, K. V. 2003. SARS-associated coronavirus. N. Engl. J. Med. 348: 1948-1951.
9. Du, L., R. Y. Kao, Y. Zhou, Y. He, G. Zhao, C. Wong, S. Jiang, K. Y. Yuen, D. Y. Jin, and B. J. Zheng. 2007. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem. Biophys. Res. Commun. 359: 174-179.
10. Li, W., M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, et al. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454.
11. Bosch, B. J., R. van der Zee, C. A. de Haan, and P. J. Rottier. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77: 8801-8811.
12. Buchholz, U. J., A. Bukreyev, L. Yang, E. W. Lamirande, B. R. Murphy, K. Subbarao, and P. L. Collins. 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA 101: 9804-9809.
13. Bisht, H., A. Roberts, L. Vogel, A. Bukreyev, P. L. Collins, B. R. Murphy, K. Subbarao, and B. Moss. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 101: 6641-6646.
14. Yang, Z. Y., W. P. Kong, Y. Huang, A. Roberts, B. R. Murphy, K. Subbarao, and G. J. Nabel. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428: 561-564.
15. Tang, L., Q. Zhu, E. Qin, M. Yu, Z. Ding, H. Shi, X. Cheng, C. Wang, G. Chang, Q. Zhu, et al. 2004. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 23: 391-394.
16. Zhao, P., J. S. Ke, Z. L. Qin, H. Ren, L. J. Zhao, J. G. Yu, J. Gao, S. Y. Zhu, and Z. T. Qi. 2004. DNA vaccine of SARS-Cov S gene induces antibody response in mice. Acta Biochim. Biophys. Sin. 36: 37-41.
17. Zhou, Z., P. Post, R. Chubet, K. Holtz, C. McPherson, M. Petric, and M. Cox. 2006. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24: 3624-3631.
18. Liu, R. Y., L. Z. Wu, B. J. Huang, J. L. Huang, Y. L. Zhang, M. L. Ke, J. M. Wang, W. P. Tan, R. H. Zhang, H. K. Chen, et al. 2005. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 112: 24-31.
19. Spruth, M., O. Kistner, H. Savidis-Dacho, E. Hitter, B. Crowe, M. Gerencer, P. Bruhl, L. Grillberger, M. Reiter, C. Tauer, et al. 2006. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24: 652-661.
20. Zhao, B., N. Y. Jin, R. L. Wang, L. S. Zhang, and Y. J. Zhang. 2006. Immunization of mice with a DNA vaccine based on severe acute respiratory syndrome coronavirus spike protein fragment 1. Viral Immunol. 19: 518-524.
21. Bukreyev, A., E. W. Lamirande, U. J. Buchholz, L. N. Vogel, W. R. Elkins, M. St. Claire, B. R. Murphy, K. Subbarao, and P. L. Collins. 2004. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363: 2122-2127.
22. Chen, Z., L. Zhang, C. Qin, L. Ba, C. E. Yi, F. Zhang, Q. Wei, T. He, W. Yu, J. Yu, et al. 2005. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79: 2678-2688.
23. Faber, M., E. W. Lamirande, A. Roberts, A. B. Rice, H. Koprowski, B. Dietzschold, and M. J. Schnell. 2005. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV neutralizing antibodies. J. Gen. Virol. 86: 1435-1440.
24. Gao, W., A. Tamin, A. Soloff, L. D'Aiuto, E. Nwanegbo, P. D. Robbins, W. J. Bellini, S. Barratt-Boyes, and A. Gambotto. 2003. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362: 1895-1896.
25. Kapadia, S. U., J. K. Rose, E. Lamirande, L. Vogel, K. Subbarao, and A. Roberts. 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340: 174-182.
26. Lee, J. S., H. Poo, D. P. Han, S. P. Hong, K. Kim, M. W. Cho, E. Kim, M. H. Sung, and C. J. Kim. 2006. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. 80: 4079-4087.
27. Weingartl, H., M. Czub, S. Czub, J. Neufeld, P. Marszal, J. Gren, G. Smith, S. Jones, R. Proulx, Y. Deschambault, et al. 2004. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78: 12672-12676.
28. Czub, M., H. Weingartl, S. Czub, R. He, and J. Cao. 2005. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23: 2273-2279.
29. Du, L., G. Zhao, Y. He, Y. Guo, B. J. Zheng, S. Jiang, and Y. Zhou. 2007. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25: 2832-2838.
30. He, Y., H. Lu, P. Siddiqui, Y. Zhou, and S. Jiang. 2005. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174: 4908-4915.
31. He, Y., Y. Zhou, S. Liu, Z. Kou, W. Li, M. Farzan, and S. Jiang. 2004. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324: 773-781.
32. Zakhartchouk, A. N., C. Sharon, M. Satkunarajah, T. Auperin, S. Viswanathan, G. Mutwiri, M. Petric, R. H. See, R. C. Brunham, B. B. Finlay, et al. 2007. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 25: 136-143.
33. Blankinship, M. J., P. Gregorevic, J. M. Allen, S. Q. Harper, H. Harper, C. L. Halbert, D. A. Miller, and J. S. Chamberlain. 2004. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10: 671-678.
34. Bouchard, S., T. C. MacKenzie, A. P. Radu, S. Hayashi, W. H. Peranteau, N. Chirmule, and A. W. Flake. 2003. Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice. J. Gene Med. 5: 941-950.
35. Amiss, T. J., D. M. McCarty, A. Skulimowski, and R. J. Samulski. 2003. Identification and characterization of an adeno-associated virus integration site in CV-1 cells from the African green monkey. J. Virol. 77: 1904-1915.
36. Xin, K. Q., T. Ooki, H. Mizukami, K. Hamajima, K. Okudela, K. Hashimoto, Y. Kojima, N. Jounai, Y. Kumamoto, S. Sasaki, et al. 2002. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum. Gene Ther. 13: 1571-1581.
37. Xin, K. Q., M. Urabe, J. Yang, K. Nomiyama, H. Mizukami, K. Hamajima, H. Nomiyama, T. Saito, M. Imai, J. Monahan, et al. 2001. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12: 1047-1061.
38. Hara, H., A. Monsonego, K. Yuasa, K. Adachi, X. Xiao, S. Takeda, K. Takahashi, H. L. Weiner, and T. Tabira. 2004. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimers Dis. 6: 483-488.
39. Wendtner, C. M., D. M. Kofler, H. D. Theiss, C. Kurzeder, R. Buhmann, C. Schweighofer, L. Perabo, S. Danhauser-Riedl, J. Baumert, W. Hiddemann, et al. 2002. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 100: 1655-1661.
40. Ponnazhagan, S., G. Mahendra, D. T. Curiel, and D. R. Shaw. 2001. Adenoassociated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J. Virol. 75: 9493-9501.
41. Zaiss, A. K., and D. A. Muruve. 2005. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5: 323-331.
42. Du, L., Y. He, Y. Wang, H. Zhang, S. Ma, C. K. Wong, S. H. Wu, F. Ng, J. D. Huang, K. Y. Yuen, et al. 2006. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines. Virology 353: 6-16.
43. Mancheno-Corvo, P., and P. Martin-Duque. 2006. Viral gene therapy. Clin. Transl. Oncol. 8: 858-867.
44. Qu, D., B. Zheng, X. Yao, Y. Guan, Z. H. Yuan, N. S. Zhong, L. W. Lu, J. P. Xie, and Y. M. Wen. 2005. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 23: 924-931.
45. Yao, X., B. Zheng, J. Zhou, D. Z. Xu, K. Zhao, S. H. Sun, Z. H. Yuan, and Y. M. Wen. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25: 1771-1779.
46. + T cells promote cellular immune responses. Vaccine 25: 6981-6991.
47. Zheng, B. J., Y. Guan, Q. Tang, C. Du, F. Y. Xie, M. L. He, K. W. Chan, K. L. Wong, E. Lader, M. C. Woodle, et al. 2004. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir. Ther. 9: 365-374.
48. Zheng, B. J., M. H. Ng, K. W. Chan, S. Tam, P. C. Woo, S. P. Ng, and K. Y. Yuen. 2002. A single dose of oral DNA immunization delivered by attenuated Salmonella typhimurium down-regulates transgene expression in HBsAg transgenic mice. Eur. J. Immunol. 32: 3294-3304.
49. Zheng, B. J., M. H. Ng, L. F. He, X. Yao, K. W. Chan, K. Y. Yuen, and Y. M. Wen. 2001. Therapeutic efficacy of hepatitis B surface antigen-antibodies- recombinant DNA composite in HBsAg transgenic mice. Vaccine 19: 4219-4225.
50. Marshall, E., and M. Enserink. 2004. Medicine. Caution urged on SARS vaccines. Science 303: 944-946.
51. Sheets, R. L., J. Stein, T. S. Manetz, C. Andrews, R. Bailer, J. Rathmann, and P. L. Gomez. 2006. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol. Sci. 91: 620-630.
52. Bisht, H., A. Roberts, L. Vogel, K. Subbarao, and B. Moss. 2005. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 334: 160-165.
53. Zhi, Y., J. Figueredo, G. P. Kobinger, H. Hagan, R. Calcedo, J. R. Miller, G. Gao, and J. M. Wilson. 2006. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum. Gene Ther. 17: 500-506.
54. Kuck, D., T. Lau, B. Leuchs, A. Kern, M. Muller, L. Gissmann, and J. A. Kleinschmidt. 2006. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J. Virol. 80: 2621-2630.
55. Chao, H., Y. Liu, J. Rabinowitz, C. Li, R. J. Samulski, and C. E. Walsh. 2000. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2: 619-623.
56. Crotty, S., B. L. Lohman, F. X. Lu, S. Tang, C. J. Miller, and R. Andino. 1999. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J. Virol. 73: 9485-9495.
57. Chen, A. Y., S. R. Fry, J. Forbes-Faulkner, G. Daggard, and T. K. Mukkur. 2006. Evaluation of the immunogenicity of the P97R1 adhesin of Mycoplasma hyopneumoniae as a mucosal vaccine in mice. J. Med. Microbiol. 55: 923-929.
58. Wang, D., E. R. Kandimalla, D. Yu, J. X. Tang, and S. Agrawal. 2005. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine 23: 2614-2622.
59. Fu, T. M., S. A. Dubey, D. V. Mehrotra, D. C. Freed, W. L. Trigona, L. Adams-Muhler, J. H. Clair, T. G. Evans, R. Steigbigel, J. M. Jacobson, et al. 2007. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res. Hum. Retrovir. 23: 67-76.
60. + patients. Cell. Immunol. 237: 96-105.
61. Charley, B., S. Riffault, and K. Van Reeth. 2006. Porcine innate and adaptative immune responses to influenza and coronavirus infections. Ann. NY Acad. Sci. 1081: 130-136.
62. Hernandez, Y. J., J. Wang, W. G. Kearns, S. Loiler, A. Poirier, and T. R. Flotte. 1999. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73: 8549-8558.
63. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76: 2667-2675.
64. Tenenbaum, L., E. Lehtonen, and P. E. Monahan. 2003. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr. Gene Ther. 3: 545-565.
65. Owens, R. A. 2002. Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS1. Curr. Gene Ther. 2: 145-159.
66. Chunling, M., Y. Kun, X. Jian, Q. Jian, S. Hua, and Z. Minsheng. 2006. Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice. Intervirology 49: 307-318.